CD28 and neoplasm: Anti-CD3/anti-CD28 and rhIL-2 activated CD3+ marrow-infiltrating lymphocytes (aMILs)52,53 were CFSE labeled and added to autologous BM that had been pulsed with either tumor cell lysate (tumor-specific antigen) or nonspecific antigen in the presence or absence of autologous CD4+/CD25+ Tregs isolated from the same patient’s BM.